This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stearns, M. E. Articles by Wang, M. Search for Related Content PubMed PubMed Citation Articles by Stearns, M. E. Articles by Wang, M.

Type IV Collagenase (M_r 72,000) Expression in Human Prostate: Benign and Malignant Tissue¹

Department of Pathology, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129

The expression of type IV collagenase (M_r 72,000) has been examined in tissues from patients with benign prostatic hyperplasia (6 patients) and varying Gleason grades of malignant prostate cancer (18 patients). Immunoperoxidase labeling indicated that expression of the type IV collagenase was weak or nonexistent in benign tissue but consistently strong in the glandular and ductal epithelial cells of prostate tumors diagnosed at Gleason grades 1–8. In moderate to advanced cancer (i.e., Gleason grades 2 to 8), invasive tumor foci in the stromal tissue produced relatively modest amounts of type IV collagenase. The normal stromal tissue (i.e., fibroblasts) uniformly failed to produce detectable levels of type IV collagenase in the 24 patients examined. Northern and quantitative slot blot hybridization assays demonstrated that collagenase type IV mRNA levels were low in benign tissue and high in malignant tumors. In contrast, the stromal cells did not express significant amounts of type IV collagenase mRNA. Enzyme-linked immunosorbent assays demonstrated that the amounts of type IV collagenase protein correlated directly with the mRNA levels in the tumor tissue. The studies suggest that type IV collagenase may be selectively overexpressed by malignant, preinvasive prostatic epithelial cells.

¹ Supported by NIH Grant CA58716 to M. E. S.

² To whom requests for reprints should be addressed, at Department of Pathology, Medical College of Pennsylvania, 3300 Henry Avenue, Philadelphia, PA 19129.

Received 7/24/92. Accepted 12/ 4/92.

This article has been cited by other articles:

				L. Xu, Y. Ding, W. J. Catalona, X. J. Yang, W. F. Anderson, B. Jovanovic, K. Wellman, J. Killmer, X. Huang, K. A. Scheidt, et al. MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells J Natl Cancer Inst, August 19, 2009; 101(16): 1141 - 1155. [Abstract] [Full Text] [PDF]

				Z. Dong, R. D. Bonfil, S. Chinni, X. Deng, J. C. Trindade Filho, M. Bernardo, U. Vaishampayan, M. Che, B. F. Sloane, S. Sheng, et al. Matrix Metalloproteinase Activity and Osteoclasts in Experimental Prostate Cancer Bone Metastasis Tissue Am. J. Pathol., April 1, 2005; 166(4): 1173 - 1186. [Abstract] [Full Text] [PDF]

				M. J. Wilson, A. Jiang, C. Wiehr, X. Wang, A. A. Sinha, and D. Pei Limited Processing of Pro-Matrix Metalloprotease-2 (Gelatinase A) Overexpressed by Transfection in PC-3 Human Prostate Tumor Cells: Association With Restricted Cell Surface Localization of Membrane-Type Matrix Metalloproteinase-1 J Androl, March 1, 2004; 25(2): 274 - 285. [Abstract] [Full Text] [PDF]

				C. Fieber, P. Baumann, R. Vallon, C. Termeer, J. C. Simon, M. Hofmann, P. Angel, P. Herrlich, and J. P. Sleeman Hyaluronan-oligosaccharide-induced transcription of metalloproteases J. Cell Sci., January 15, 2004; 117(2): 359 - 367. [Abstract] [Full Text] [PDF]

				D. Trudel, Y. Fradet, F. Meyer, F. Harel, and B. Tetu Significance of MMP-2 Expression in Prostate Cancer: an Immunohistochemical Study Cancer Res., December 1, 2003; 63(23): 8511 - 8515. [Abstract] [Full Text] [PDF]

				U. Mahmood and R. Weissleder Near-Infrared Optical Imaging of Proteases in Cancer Mol. Cancer Ther., May 1, 2003; 2(5): 489 - 496. [Abstract] [Full Text] [PDF]

				P. Sweeney, T. Karashima, S.-J. Kim, D. Kedar, B. Mian, S. Huang, C. Baker, Z. Fan, D. J. Hicklin, C. A. Pettaway, et al. Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production Clin. Cancer Res., August 1, 2002; 8(8): 2714 - 2724. [Abstract] [Full Text] [PDF]

				F. A. Attiga, P. M. Fernandez, A. T. Weeraratna, M. J. Manyak, and S. R. Patierno Inhibitors of Prostaglandin Synthesis Inhibit Human Prostate Tumor Cell Invasiveness and Reduce the Release of Matrix Metalloproteinases Cancer Res., August 1, 2000; 60(16): 4629 - 4637. [Abstract] [Full Text]

				A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian Matrix Metalloproteinases: Biologic Activity and Clinical Implications J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135. [Abstract] [Full Text] [PDF]

				T. Sato, T. Kondo, T. Fujisawa, M. Seiki, and A. Ito Furin-independent Pathway of Membrane Type 1-Matrix Metalloproteinase Activation in Rabbit Dermal Fibroblasts J. Biol. Chem., December 24, 1999; 274(52): 37280 - 37284. [Abstract] [Full Text] [PDF]

				J. Upadhyay, B. Shekarriz, J. A. Nemeth, Z. Dong, G. D. Cummings, R. Fridman, W. Sakr, D. J. Grignon, and M. L. Cher Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) and MMP-2 Immunolocalization in Human Prostate: Change in Cellular Localization Associated with High-Grade Prostatic Intraepithelial Neoplasia Clin. Cancer Res., December 1, 1999; 5(12): 4105 - 4110. [Abstract] [Full Text] [PDF]

				K.L. Pickett, G.J. Harber, A.A. DeCarlo, P. Louis, S. Shaneyfelt, L.J. Windsor, and M.K. Bodden 92K-GL (MMP-9) and 72K-GL (MMP-2) are Produced in vivo by Human Oral Squamous Cell Carcinomas and can Enhance FIB-CL (MMP-1) Activity in vitro Journal of Dental Research, July 1, 1999; 78(7): 1354 - 1361. [Abstract] [PDF]